|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||120.65 - 123.80|
|52-week range||110.80 - 200.50|
|Beta (5Y monthly)||0.80|
|PE ratio (TTM)||19.36|
|Earnings date||02 Aug 2022|
|Forward dividend & yield||2.63 (2.16%)|
|Ex-dividend date||04 Aug 2022|
|1y target est||174.35|
Royal DSM, a global purpose-led science-based company, today announces the completion of its acquisition of Prodap, a leading animal nutrition and technology company in Brazil, which was first announced on 7 June 2022.
Royal DSM, a global purpose-led science-based company, today announces the completion of the sale of its Protective Materials business to Avient Corporation for an Enterprise Value of €1.45 billion. The agreement was initially announced on 20 April 2022.
Royal DSM, a global purpose-led science-based company, announces that it pledges to purchase all of its electricity worldwide from renewable sources as well as further reduce greenhouse gas (GHG) emissions from its own operations faster with stringent new 2030 sustainability targets.